The Dawn of Precision Medicine in Neurodegenerative Diseases
We are on the precipice of Precision Medicine in neurodegenerative diseases (NDDs)
Precision Medicine is a rapidly evolving market, with technologies such as liquid biopsy, gene therapy, and spatial omic imaging set to change treatment paradigms and improve clinical outcomes for patients. However, this complexity offers unique challenges for our clients as they grapple with the impact Precision Medicine will have across their business - from R&D to supply chain, through to commercialization, and also as they seek to acquire new technologies through licensing or acquisition. Our industry depth, decades long experience, and local market knowledge means we deliver the critical insights needed to inform the key strategic decisions our clients must take to be market leaders in Precision Medicine.
Thought Leadership
Conferences
Global Precision Medicine Panel at JP Morgan
Click on the video to watch our global and US HCLS Deal Advisory and Strategy leader Kristin Pothier at the 2023 JP Morgan Healthcare Conference as she leads a panel discussion on the challenges and opportunities in the global precision medicine field.
Cures on Horizon
People are often hesitant in using the word “cure” in the biotech sector. Watch why KPMG is interested in “cures”, and what are the upcoming opportunities and challenges
The real keys to innovative deal making in Precision Medicine in 2022
Industry leaders Kristin Pothier, KPMG Global Deal Advisory and Strategy Leader for Healthcare and Life Sciences, and Bonnie Anderson, Chairwoman and former CEO of Veracyte, talk about how strategic deals transformed the company and enabled its growth to market leadership.
Pain Points and Potential for Cell and Gene Therapies
Cell and gene therapies have the potential to transform the lives of patients and their families. As judged by patients' perspectives and experiences, how close are we to realizing this potential?
How Should We Value a Cure?
In the landscape of new, potentially curative cell and gene therapies, many uncertainties remain including how to pay for them. Value assessment approaches have been looked to as a way to achieve higher-value healthcare and many efforts are aimed at centering the patient perspective.
Visit the KPMG in Precision Medicine page
